Drug Profile
T cell replacement therapy - Kiadis Pharma
Alternative Names: ATIR; ATIR-101; ATIR-201; ATIR101; Reviroc™; Rhitol™; T cell replacement therapy TH9402Latest Information Update: 23 Jun 2022
Price :
$50
*
At a glance
- Originator University of Montreal
- Developer Kiadis Pharma
- Class Haematopoietic stem cells therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Graft-versus-host disease
- Phase III Acute myeloid leukaemia
- Phase II Bone marrow transplant rejection; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I/II Beta-thalassaemia
- Discontinued Chronic myeloid leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 24 May 2022 Kiadis Pharma terminates phase-III III HATCY trial in graft-versus-host disease in Belgium, Canada, Croatia, France, Germany, Israel, Italy, Netherlands, Portugal, Spain, Sweden, UK and USA (NCT02999854)
- 16 Apr 2021 Kiadis Pharma has been acquired by Sanofi
- 17 Oct 2019 Kiadis Pharma announces intention to resubmit marketing authorization application with the EMA after the conclusion of the ongoing phase III trial